Division of Sports Medicine, Department of Internal Medicine, University Hospital Ulm, Leimgrubenweg 12-14, 89075, Ulm, Germany,
Sports Med. 2013 Nov;43(11):1089-100. doi: 10.1007/s40279-013-0081-6.
Skeletal muscle regeneration efficiency declines with age for both men and women. This decline impacts on functional capabilities in the elderly and limits their ability to engage in regular physical activity and to maintain independence. Aging is associated with a decline in sex hormone production. Therefore, elucidating the effects of sex hormone substitution on skeletal muscle homeostasis and regeneration after injury or disuse is highly relevant for the aging population, where sarcopenia affects more than 30 % of individuals over 60 years of age. While the anabolic effects of androgens are well known, the effects of estrogens on skeletal muscle anabolism have only been uncovered in recent times. Hence, the purpose of this review is to provide a mechanistic insight into the regulation of skeletal muscle regenerative processes by both androgens and estrogens. Animal studies using estrogen receptor (ER) antagonists and receptor subtype selective agonists have revealed that estrogens act through both genomic and non-genomic pathways to reduce leukocyte invasion and increase satellite cell numbers in regenerating skeletal muscle tissue. Although animal studies have been more conclusive than human studies in establishing a role for sex hormones in the attenuation of muscle damage, data from a number of recent well controlled human studies is presented to support the notion that hormonal therapies and exercise induce added positive effects on functional measures and lean tissue mass. Based on the fact that aging human skeletal muscle retains the ability to adapt to exercise with enhanced satellite cell activation, combining sex hormone therapies with exercise may induce additive effects on satellite cell accretion. There is evidence to suggest that there is a 'window of opportunity' after the onset of a hypogonadal state such as menopause, to initiate a hormonal therapy in order to achieve maximal benefits for skeletal muscle health. Novel receptor subtype selective ligands and selective estrogen and androgen receptor modulators (SERMs, SARMs) promise to reduce health risks associated with classical hormonal therapies, whilst maintaining the positive effects on muscle repair. Dietary supplements containing compounds with structural similarity to estrogens (phytoestrogens) are increasingly used as alternatives to classical hormone-replacement therapies (HRT), but the effects on skeletal muscle are currently largely unknown. Research has started to investigate the combined effects of exercise and alternative HRTs, such as soy isoflavones, on skeletal muscle regenerative processes to provide safer and more efficient therapies to promote muscle regeneration and maintenance of muscle mass and strength in the aging population.
骨骼肌的再生效率会随着男性和女性年龄的增长而下降。这种下降会影响老年人的身体机能,限制他们进行常规体育活动和保持独立性的能力。衰老与性激素产生的下降有关。因此,阐明性激素替代对损伤或废用后骨骼肌内稳态和再生的影响,对于老龄化人口非常重要,在 60 岁以上的人群中,超过 30%的人患有肌肉减少症。虽然雄激素的合成代谢作用已被广泛了解,但雌激素对骨骼肌合成代谢的影响直到最近才被发现。因此,本综述的目的是提供一个机制上的见解,了解雄激素和雌激素对骨骼肌再生过程的调节。使用雌激素受体 (ER) 拮抗剂和受体亚型选择性激动剂的动物研究表明,雌激素通过基因组和非基因组途径发挥作用,减少白细胞浸润并增加再生骨骼肌组织中的卫星细胞数量。尽管动物研究比人类研究更能确定性激素在减轻肌肉损伤中的作用,但提出了一些最近的对照良好的人类研究数据,以支持这样一种观点,即激素治疗和运动对功能测量和瘦组织质量产生额外的积极影响。基于这样一个事实,即衰老的人类骨骼肌通过增强卫星细胞激活来适应运动,将性激素治疗与运动相结合可能会对卫星细胞积累产生附加作用。有证据表明,在进入低睾丸激素状态(如绝经)后,存在一个“机会之窗”,可以开始激素治疗,以获得对骨骼肌健康的最大益处。新型受体亚型选择性配体和选择性雌激素和雄激素受体调节剂 (SERMs、SARMs) 有望降低与经典激素治疗相关的健康风险,同时保持对肌肉修复的积极影响。含有与雌激素结构相似的化合物的膳食补充剂(植物雌激素)越来越多地被用作经典激素替代疗法 (HRT) 的替代品,但目前对骨骼肌的影响在很大程度上仍不清楚。研究已经开始研究运动和替代 HRT(如大豆异黄酮)的联合作用对骨骼肌再生过程的影响,以提供更安全、更有效的治疗方法,促进肌肉再生和维持老龄化人口的肌肉量和力量。